Michael Vi/iStock Editorial via Getty Images Roche ( OTCQX:RHHBY ) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its primary goal in a global Phase 3 trial, indicating a reduction in influenza virus transmission. The new findings build on the existing benefits of Xofluza, which.